These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 28076376)

  • 1. Increased Natural Killer Cell Activation in HIV-Infected Immunologic Non-Responders Correlates with CD4+ T Cell Recovery after Antiretroviral Therapy and Viral Suppression.
    Luo Z; Li Z; Martin L; Hu Z; Wu H; Wan Z; Kilby M; Heath SL; Huang L; Jiang W
    PLoS One; 2017; 12(1):e0167640. PubMed ID: 28076376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy.
    Luo Z; Li Z; Martin L; Wan Z; Meissner EG; Espinosa E; Wu H; Yu X; Fu P; Julia Westerink MA; Kilby JM; Wu J; Huang L; Heath SL; Li Z; Jiang W
    J Infect Dis; 2017 Jul; 216(1):82-91. PubMed ID: 28498953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant natural killer (NK) cell activation and dysfunction among ART-treated HIV-infected adults in an African cohort.
    Nabatanzi R; Bayigga L; Cose S; Rowland-Jones S; Canderan G; Joloba M; Nakanjako D
    Clin Immunol; 2019 Apr; 201():55-60. PubMed ID: 30817998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
    Offersen R; Nissen SK; Rasmussen TA; Østergaard L; Denton PW; Søgaard OS; Tolstrup M
    J Virol; 2016 May; 90(9):4441-4453. PubMed ID: 26889036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.
    Chehimi J; Azzoni L; Farabaugh M; Creer SA; Tomescu C; Hancock A; Mackiewicz A; D'Alessandro L; Ghanekar S; Foulkes AS; Mounzer K; Kostman J; Montaner LJ
    J Immunol; 2007 Aug; 179(4):2642-50. PubMed ID: 17675528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of in vitro stimulation with lipopolysaccharide on T-cell activation in HIV-infected antiretroviral-treated patients.
    Tincati C; Bellistrì GM; Ancona G; Merlini E; d'Arminio Monforte A; Marchetti G
    Clin Dev Immunol; 2012; 2012():935425. PubMed ID: 22400042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased early activation of CD56dimCD16dim/- natural killer cells in immunological non-responders correlates with CD4+ T-cell recovery.
    Zhang QY; Zhang X; Su B; Liu LF; Yang XD; Tang B; Xia H; Ma P; Zhang T; Wu H
    Chin Med J (Engl); 2020 Nov; 133(24):2928-2939. PubMed ID: 33252378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation.
    Lichtfuss GF; Cheng WJ; Farsakoglu Y; Paukovics G; Rajasuriar R; Velayudham P; Kramski M; Hearps AC; Cameron PU; Lewin SR; Crowe SM; Jaworowski A
    J Immunol; 2012 Aug; 189(3):1491-9. PubMed ID: 22745371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy - CTN PT006: study protocol for a randomized controlled trial.
    Lebouché B; Jenabian MA; Singer J; Graziani GM; Engler K; Trottier B; Thomas R; Brouillette MJ; Routy JP
    Trials; 2014 Oct; 15():390. PubMed ID: 25293882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.
    Bayigga L; Nabatanzi R; Sekiziyivu PN; Mayanja-Kizza H; Kamya MR; Kambugu A; Olobo J; Kiragga A; Kirimunda S; Joloba M; Nakanjako D
    BMC Immunol; 2014 Jan; 15():2. PubMed ID: 24483185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and Function of NKG2D Is Impaired in CD8+ T Cells of Chronically HIV-1-Infected Patients Without ART.
    Giuliani E; Vassena L; Desimio MG; Buonomini AR; Malagnino V; Andreoni M; Doria M
    J Acquir Immune Defic Syndr; 2015 Dec; 70(4):347-56. PubMed ID: 26509932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of plasma auto-IgGs on CD4
    Luo Z; Zhou Z; Ogunrinde E; Zhang T; Li Z; Martin L; Wan Z; Wu H; Qin Z; Ou T; Zhang J; Ma L; Liao G; Heath S; Huang L; Jiang W
    J Leukoc Biol; 2017 Dec; 102(6):1481-1486. PubMed ID: 29030391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals.
    Powell AM; Luo Z; Martin L; Wan Z; Ma L; Liao G; Song Y; Li X; Michael Kilby J; Huang L; Jiang W
    Vaccine; 2017 Feb; 35(5):831-841. PubMed ID: 28017428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased NKG2A found in cytotoxic natural killer subset in HIV-1 patients with advanced clinical status.
    Zhang R; Xu J; Hong K; Yuan L; Peng H; Tang H; Ma P; Zhang Y; Xing H; Ruan Y; Shao Y
    AIDS; 2007 Dec; 21 Suppl 8():S9-17. PubMed ID: 18172398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
    Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
    J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.
    d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V
    J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKG2C is a major triggering receptor involved in the V[delta]1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells.
    Fausther-Bovendo H; Wauquier N; Cherfils-Vicini J; Cremer I; Debré P; Vieillard V
    AIDS; 2008 Jan; 22(2):217-26. PubMed ID: 18097224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells.
    Noyan K; Nguyen S; Betts MR; Sönnerborg A; Buggert M
    Front Immunol; 2018; 9():19. PubMed ID: 29403500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.